New U.S. biosimilar launches of top products 2024-2029

Published by
Matej Mikulic,
Nov 29, 2024

This statistic shows the number of biosimilar launches of select major biologics until 2029. For Johnson & Johnson's blockbuster drug Stelara, a targeted antibody therapy used to manage inflammatory conditions, it is estimated that from Q1 2025 on, eight biosimilars will be available.

New biosimilar launches of select major products in the United States between 2024 and 2029

© Statista 2024
Download
Show detailed source information?
Register for free
Already a member?
Log in
Source

Use Ask Statista Research Service

Release date

2024

Region

United States

Survey time period

As of September 2024

Supplementary notes

* Number of identified Phase 3+ biosimilars aligned to reference product.

Citation formats
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Register now
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts

Statistics on " Generics and biosimilars "

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Generics and biosimilars

Global overview

5

Top companies

5

U.S. market

6

Patent expiration

3

Savings

7

Biosimilars

7

Further Content: You might find this interesting as well

Topics

Global pharmaceutical industryPharmaceutical industry in the U.S.Top pharmaceutical drugsDrug pricing in the U.S.Medical debt in the U.S.
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Register now
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts
Learn more about how Statista can support your business.